July 11, 2005 11:00 ET

Evidence and Acceptance Grows For Taking Statin Drugs to Treat Dementia; Nymox (NASDAQ:NYMX) Has Global Patent Rights for Statin Drugs for the Treatment and Prevention of Alzheimer's Disease

MAYWOOD, N.J.--(CCNMatthews - Jul 11, 2005) -

Nymox Pharmaceutical Corporation's (NASDAQ:NYMX) U.S. and global patent rights and prospects for the use of statin drugs for treating, preventing or reducing the risk of Alzheimer's disease (AD) in patients at risk for the disease have been supported by growing scientific evidence and acceptance by doctors. Published studies have shown that doctors favor the use of statins for treating patients at risk for developing cognitive impairment and dementia. Many studies have shown up to 70% reduction in AD incidence in individuals who use statin drugs.

Nymox Pharmaceutical Corporation holds U.S. and global patent rights for the use of statin drugs for the prevention and treatment of Alzheimers disease (AD), including for patients at risk for AD because of vascular-related risk factors or disease. Statins are a class of cholesterol-lowering drugs that are the biggest-selling prescription pills in pharmaceutical history with estimated 2004 global sales of up to $26 billion. Alzheimer's disease is the leading cause of dementia in the elderly, afflicting an estimated 4.5 million people in the U.S. alone.

Taking a statin drug reduces the risk of all types of dementia, including Alzheimer's disease, by 44% according to a large study of 8,574 patients published in a recent issue of Neurology (May, 2005; 64:1531-8). In the study of persons aged 65 or more living in three cities in France, researchers compared the prevalence of dementia among those individuals who took a statin drug to lower their cholesterol against those who did not. Overall, the prevalence of dementia was 44% lower for those individuals taking a statin to lower cholesterol. Most of the dementia cases observed were Alzheimer's disease (65.1%).

In addition to recent studies presented at major medical conferences, published peer-reviewed studies include, for example, Journal of Neurological Sciences 2005; 229:147-150, International Journal of Geriatric Psychiatry 2004; 19:327-32; Neuroepidemiology 2004; 23:94-8; Neuron 2004; 41:7-10; Arch Neurol 2000; 57:1439-1443; Lancet 2000; 356:1627-1631; Arch Neurol 2002; 59:223-227; J Gerontol Biol Sci Med Sci 2002;57:M414-M418; and J Am Geriatr Soc 2002;50:1852-1856. The value of statins in dementia has also been discussed in medical textbooks.

The potential for the use of statin drugs to treat or reduce the risk of Alzheimer's disease has also been featured in general media such as New York Times (April 13, 2004), Fortune magazine (August 9, 2004), Newsweek magazine (Jan 19, 2004), Los Angeles Times (June 22, 2003), and The Wall Street Journal (April 17 and 18, 2002).

Nymox Pharmaceutical Corporation is a biopharmaceutical company with three unique proprietary products on the market, and a significant R&D pipeline of drug products in development. Nymox developed and is currently offering its AlzheimAlert™ test, a nationally certified clinical reference laboratory urinary test that is the world's only accurate, non-invasive aid in the diagnosis of Alzheimer's disease. The AlzheimAlert™ test is certified with a CE Mark, making the device eligible for sale in the European Union. Recently, Nymox has signed distribution agreements for AlzheimAlert™ in Italy, the Czech Republic, and Greece. Nymox also developed and markets NicAlert™ and TobacAlert™ tests that use urine or saliva to detect use of and exposure to tobacco products. NicAlert™ has received clearance from the U.S. Food and Drug Administration (FDA). TobacAlert™ is the first test of its kind to accurately measure second hand smoke exposure in individuals. The Company's TobacAlert™ product is presently available in CVS / pharmacy® stores across the U.S.

Nymox also has several drug candidates including NX-1207 for benign prostatic hyperplasia (BPH), which is in late stage development. The Company is developing new antibacterial agents for the treatment of urinary tract and other bacterial infections in humans and for the treatment of E. coli O157:H7 contamination in meat and other food and drink products. Nymox also is developing other novel drug treatments aimed at the causes of Alzheimer's disease.

More information about Nymox is available at www.nymox.com, email: info@nymox.com, or 800-936-9669.

This press release contains certain "forward-looking statements" as defined in the United States Private Securities Litigation Reform Act of 1995 that involve a number of risks and uncertainties. There can be no assurance that such statements will prove to be accurate and the actual results and future events could differ materially from management's current expectations. Such factors are detailed from time to time in Nymox's filings with the United States Securities and Exchange Commission and other regulatory authorities.

Contact Information

  • Nymox Pharmaceutical Corporation
    Roy Wolvin, 1-800-93NYMOX